Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-10-06
1995-11-28
O'Sullivan, Peter
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
2609982, 514397, 514400, 514414, 514415, 514562, 514607, 514824, 514825, 514843, 514912, 530331, 5483121, 5483131, 5483137, 5483361, 548455, 548503, A61K 3805, A61K 3806, C07K 5062, C07K 5065
Patent
active
054708346
ABSTRACT:
Novel sulfoximine and sulfodiimine matrix metalloproteinase inhibitors of the formula, ##STR1## wherein: R.sup.1 is selected from the group consisting of lower-alkyl, hydroxy lower-alkyl, amino lower-alkyl, carbamoyl lower-alkyl, lower-alkyl carbonyl, lower-alkyoxyalkyl, aralkyl and heteroaralkyl;
REFERENCES:
patent: 5171885 (1992-12-01), Griffith
patent: 5178877 (1993-01-01), Garren et al.
Schwartz et al. Progress in Medicinal Chemistry, vol. 29, 1992, Elsevier Science Publishers, pp. 271-334.
Cappalonga et al., "Structural Comparison of Sulfodiimine, etc" J. of Biol. Chem. vol. 267, No. 27 (1992) pp. 19192-19197.
Mock et al. "Sulfoximine and Sulfodiimine transistor-State Analogue Inhibitors, etc." J. Am. Chem. Soc. 1989, 111, pp. 4467-4472.
M. Brannstrom, et al., "Inhibitors of Mammalian Tissue Collagenase and Metalloproteinases Suppress Ovulation in the Perfused Rat Ovary", Endicrinology 122:1715-1721 (1988).
C. Librach, et al., "92-kD Type IV Collagenase Mediates Invasion of Human Cytotrophoblasts", J. Cell Biol. 113:437-449 (1991).
L. M. Matrisian, "The Matrix-Degrading Metalloproteinases", Bioessays 14: 455-463 (1992).
H. Birkedal-Hansen, et al., "Matrix Metalloproteinases: A Review", Crit Revs. Oral Biol. Med. 4(2): 197-250 (1993).
J. M. Delaisse, et al., "The Effects of Inhibitors of Cysteine-Proteinases and Collagenase on the Resorptive Activity of Isolated Osteoclasts", Bone 8: 305-313 (1987).
J. M. Delaisse, et al., "A New Synthetic Inhibitor of Mammalian Tissue Collagenase Inhibits Bone Resorption in Culture", Biochem. Biophys. Res. Communs. 133: 483-490 (1985).
M. A. Moses, et al., "Inhibitors of Angiogenesis (Review)", Biotechnology 9: 630-634 (1991).
R. Langer, et al., "Control of tumor growth in animals by infusion of an angiogenesis inhibitor", Proc. Natl. Acad. Sci. USA 77: 4331-4335 (1980).
J. White, "Minocycline for Dystrophic Epidermolysis Bullosa", Lancet I: 966 (1988).
P. Humbert, et al., "Tetracyclines for Dystrophic Epidermolysis Bullosa", Lancet II: 277 (1989).
F. Burns, et al., "Inhibition of Alkali-Induced Corneal Ulceration and Perforation by a Thiol Peptide", Invest. Ophthalmol. Vis. Sci. 31:107-114 (1990).
A. Henney, et al., "Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization", Proc. Natl. Acad. Sci. USA 88:8154-8158 (1991).
J. D'Arniento, et al., "Collagenase Expression in the Lungs of Transgenic Mice Causes Pulmonary Emphysema", Cell 71:955-961 (1992).
P. LeRoux, et al., "Synthesis of new peptide inhibitors of the meso-diaminopimelate-adding enzyme", Eur. J. Med. Chem. 27, 899-907 (1992).
M. Abo-Ghali, et al., "Synthesis of inhibitors of the meso-diaminopimelate-adding enzyme from Escherichia coli", Int. J. Peptide Protein Res. 32, 208-222 (1988).
Schwartz Martin A.
Van Wart Harold
Florida State University
O'Sullivan Peter
LandOfFree
Sulfoximine and suldodiimine matrix metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfoximine and suldodiimine matrix metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfoximine and suldodiimine matrix metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2013726